This study focuses on Congenital Adrenal Hyperplasia (CAH), a genetic condition that affects the body’s ability to produce certain hormones in the adrenal glands. The study will test a new medication called crinecerfont, which is given as an oral solution (liquid medicine taken by mouth) to children under 2 years of age who have this condition.
The purpose of this research is to understand how crinecerfont works in the bodies of young children with CAH, including how safe it is and how well they tolerate it. During the study, children will receive the medication for 14 days while continuing their regular hormone replacement treatment. The study will monitor how the medicine moves through their bodies and collect information about any effects they experience.
Throughout the study, researchers will take blood samples to measure the amount of medicine in the children’s bodies. They will also watch for any changes in the children’s health and record any side effects that may occur. This information will help determine if the medication might be suitable for treating young children with CAH in the future.
Germany 
